

10/593215
IAP9/Rec'd PCT/PTO 13 SEP 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gosse B. Bruinsma

Serial No.: To be assigned

Filed: September 13, 2006

For: ACETYLCHOLINESTERASE
INHIBITORS AND N-METHYL-D-
ASPARTATE ANTAGONISTS USEFUL IN
THE TREATMENT OF COGNITIVE
DISORDERS

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 3154-6311.1US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV826304575US

Date of Deposit with USPS: September 13, 2006

Person making Deposit: Brett Hooke

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

U.S. Patent Documents

U.S. Patent No.

US - 5,409,948

Publication Date

04-25-1995

Patentee

Greig et al.

Attorney Docket No.: 3154-6311.1US

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
WO 92/17168	10-15-1992	The Children's Medical Center Corporation
WO 2005/092009 A2	10-06-2005	Axonyx, Inc.


Other Documents

PCT International Search Report, PCT/US2005/009186, dated November 7, 2005.

MEMANTINE HCl, Briefing document for FDA Peripheral and Central Nervous System, Drug Advisory Committee Meeting, September 24, 2003, Available for Public Disclosure without Redaction, Release Date: August 20, 2003, Forest Laboratories, Inc., 909 Third Ave., NY, NY.

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: September 13, 2006
ACT/bv

Enclosures: Form PTO/SB/08
Cited Non-U.S. Patent Documents
Document in ProLaw

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, Washington, DC 20231.

10/593215

IAP9/Rec'd PCT/PTO 13 SEP 2006

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	To be assigned
Filing Date	September 13, 2006
First Named Inventor	Gosse B. Bruinsma
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	3154-6311 IUS

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Search Report, PCT/US2005/009186, dated November 7, 2005.	
		MEMANTINE HCl, Briefing document for FDA Peripheral and Central Nervous System, Drug Advisory Committee Meeting, September 24, 2003, Available for Public Disclosure without Redaction, Release Date: August 20, 2003, Forest Laboratories, Inc., 909 Third Ave., NY, NY.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.